Physician profile
David A Palmore
NPI 1619977444
$3,328.39
in general payments reported to CMS, 2019-2025
26 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $706 · 2021: $523 · 2022: $490 · 2023: $516 · 2024: $319 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $966.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $949.41 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.67 | 2019-2024 | Ofev |
| Allergan, INC. | $252.40 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $214.25 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $172.62 | 2019-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.00 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $154.16 | 2019-2022 | |
| Amgen INC. | $137.80 | 2019-2024 | Otezla, Repatha |
| Abbott Laboratories | $128.18 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $122.57 | 2019-2023 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $94.61 | 2020-2023 | Belsomra |
| Abbvie INC. | $63.09 | 2020-2022 | |
| Nevro Corp. | $60.47 | 2023 | Senza |
| Amarin Pharma, INC. | $53.32 | 2019-2020 | |
| Shield Therapeutics INC | $51.51 | 2023 | Accrufer |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $50.03 | 2019-2025 | |
| Exact Sciences Corporation | $41.62 | 2023-2024 | Cologuard Collection Kit |
| Eisai INC. | $40.29 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $39.39 | 2023-2025 | Quviviq, Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $35.33 | 2021-2023 | |
| Arbor Pharmaceuticals, INC. | $31.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.56 | 2020 | |
| Astellas Pharma US INC | $20.43 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.50 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Palmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.